This study – presented during an ACC.17 late breaking trial session and simultaneously published in NEJM – tracked the use of the PCSK9 inhibitor evolocumab. What were the clinical profiles of the over 27,000 high-risk patients enrolled in this multi-year trial? Were they on statins? What were the results on risk reduction in primary and secondary endpoints and why does this constitute a “beautiful regression”? Join M. Sabatine, the study’s lead author, and find the answers to these and other questions here.
This interview was recorded at the American College of Cardiology Scientific Sessions 2017 (ACC.17), ), see more videos here [ Ссылка ]
